13The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still highly debated. Recently, the StiL and the BRIGHT trials showed that the combination of rituximab and bendamustine (R-B) is non-inferior to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a better toxicity profile. Utilizing a retrospective analysis, we compared the efficacy and safety of both regimens in clinical practice. From November 1995 to January 2014, 263 LG-NHL patients treated with either R-B or R-CHOP were retrospectively assessed in seven European cancer centers. Ninety patients were treated with R-B and 173 with R-CHOP. Overall response rate was 94 and 92 % for the R-B and the R-CHOP group, respe...
We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 ve...
Fredrick Hagemeister1, George Manoukian21Department of Lymphoma/Myeloma, The University of Texas M.D...
20Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazole ...
The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still high...
Background: R-CHOP/R-CVP is the only recommended first-line treatment for Non-Hodgkin’s Lymphoma (NH...
Background: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre...
Background Chemotherapy, radiation and autologous bone marrow transplant are conventional standard t...
Bendamustine is an alkylating agent with favorable clinical activity against indolent lymphomas as ...
none13noFirst line therapy of patients with marginal zone lymphomas (MZL) is not well established an...
Background. R-CHOP-21 has remained the standard chemotherapy for aggressive non-Hodgkin's lymphoma. ...
Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) ...
Over the past 30 years, many treatment platforms have been developed for diffuse large B-cell lympho...
Rituximab (R) has changed the prognosis of patients with non-Hodgkin's lymphoma (NHL) in developed c...
Gegenstand: Diese multizentrische Studie wurde initiiert, um neue Therapieoptionen für die Behandlun...
Based on centroblast frequency, follicular lymphoma (FL) is subdivided into grades 1-2, 3A, and 3B. ...
We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 ve...
Fredrick Hagemeister1, George Manoukian21Department of Lymphoma/Myeloma, The University of Texas M.D...
20Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazole ...
The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still high...
Background: R-CHOP/R-CVP is the only recommended first-line treatment for Non-Hodgkin’s Lymphoma (NH...
Background: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre...
Background Chemotherapy, radiation and autologous bone marrow transplant are conventional standard t...
Bendamustine is an alkylating agent with favorable clinical activity against indolent lymphomas as ...
none13noFirst line therapy of patients with marginal zone lymphomas (MZL) is not well established an...
Background. R-CHOP-21 has remained the standard chemotherapy for aggressive non-Hodgkin's lymphoma. ...
Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) ...
Over the past 30 years, many treatment platforms have been developed for diffuse large B-cell lympho...
Rituximab (R) has changed the prognosis of patients with non-Hodgkin's lymphoma (NHL) in developed c...
Gegenstand: Diese multizentrische Studie wurde initiiert, um neue Therapieoptionen für die Behandlun...
Based on centroblast frequency, follicular lymphoma (FL) is subdivided into grades 1-2, 3A, and 3B. ...
We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 ve...
Fredrick Hagemeister1, George Manoukian21Department of Lymphoma/Myeloma, The University of Texas M.D...
20Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazole ...